PRP Injection and Warfarin: Procedural Management
PRP injections are not absolutely contraindicated in patients on warfarin, but warfarin must be interrupted and the INR reduced to ≤1.5 before the procedure can be safely performed.
Warfarin Management Before PRP Injection
PRP injections should be classified as procedures requiring adequate hemostasis. Based on perioperative anticoagulation guidelines, the following protocol applies:
Pre-Procedure Warfarin Interruption
- Discontinue warfarin 5 days before the PRP injection to allow adequate INR reduction 1
- For patients with baseline INR 2.0-3.0, this 5-day washout period typically reduces INR to ≤1.5 within 115 hours 1
- Target INR ≤1.5 is required before proceeding with the injection 1
Pre-Procedure INR Monitoring
- Check INR 1-2 days before the scheduled procedure 1
- If INR remains elevated (>1.5-1.8), consider administering low-dose oral vitamin K (1-2.5 mg) for reversal 1
- Confirm INR ≤1.5 on the day of procedure before proceeding
Special Considerations for Longer Washout
Certain patients require longer than 5 days of warfarin interruption 1:
- Elderly patients
- Patients with high-intensity INR targets (3.0-4.0)
- Patients on longer-acting coumarins
Bridging Anticoagulation Decision
Whether bridging therapy is needed depends on the patient's thromboembolic risk:
High Thromboembolic Risk (requires bridging)
- Mechanical mitral valve
- Mechanical aortic valve with stroke risk factors
- Recent VTE (<3 months)
- Atrial fibrillation with CHADS₂ score ≥5
Low-Moderate Thromboembolic Risk (no bridging needed)
- Mechanical aortic valve without stroke risk factors 1
- Atrial fibrillation with CHADS₂ score <5
- Remote VTE (>12 months)
For most patients receiving PRP injections, bridging is NOT required as PRP is a low-to-moderate bleeding risk procedure and most candidates have lower thromboembolic risk profiles 1.
Post-Procedure Warfarin Resumption
- Resume warfarin at the usual maintenance dose on the evening of the procedure or the next morning once adequate hemostasis is confirmed 2, 1
- The 2022 ACCP guidelines suggest against routinely doubling the warfarin dose post-procedure 2
- Continue monitoring INR until therapeutic range is re-established
Critical Caveats
Why Warfarin Must Be Stopped
Unlike simple joint injections where warfarin continuation may be safe with INR <3 3, PRP injections have unique requirements:
- PRP efficacy depends on intact platelet function - Warfarin itself doesn't directly impair platelet function, but the procedure requires normal coagulation for optimal PRP preparation and delivery 4
- Bleeding risk at injection site - While joint injections in anticoagulated patients show safety 3, PRP procedures often involve larger volumes and multiple injection sites
- Quality of PRP preparation - Anticoagulated blood may affect the centrifugation process and final platelet concentrate quality
Common Pitfalls to Avoid
- Do not perform PRP injection with therapeutic INR - Unlike simple corticosteroid joint injections where continuation of warfarin may be acceptable 3, PRP requires normal coagulation
- Do not assume 5 days is sufficient for all patients - Always verify INR before proceeding
- Do not forget to assess thromboembolic risk - High-risk patients may need bridging anticoagulation during the warfarin interruption period
- Do not resume warfarin too early - Ensure adequate hemostasis at the injection site before restarting
Additional Medication Considerations
While managing warfarin, also address other medications that affect PRP efficacy 5, 6:
- Stop aspirin 7-10 days before PRP injection
- Stop non-selective NSAIDs (ibuprofen 24 hours, naproxen 48 hours before)
- COX-2 selective NSAIDs and statins do not require discontinuation 5
Algorithm Summary
- 7-10 days before: Stop aspirin and assess thromboembolic risk
- 5 days before: Stop warfarin (longer if elderly or high baseline INR)
- 1-2 days before: Check INR; give vitamin K 1-2.5 mg PO if INR >1.5-1.8
- Day of procedure: Confirm INR ≤1.5 before proceeding
- Post-procedure: Resume warfarin at usual dose once hemostasis achieved
- Follow-up: Monitor INR until therapeutic range re-established
This approach balances the bleeding risk of the procedure against thromboembolic risk during the interruption period, while optimizing conditions for PRP efficacy.